| Health Bill Limits Premiums for Young Adults Insurers and employers will not be able to charge higher rates for young adults who remain on their parents' health insurance plans than they charge for younger children on those plans. online.wsj.com |
Celgene: Growth by Acquisition Jason Chew submits: During the last decade, Celgene (CELG) has been one of the best performing stocks. With a market cap in the year 2000 of just $2.4 billion, it has grown to become the third largest biotech company behind Amgen (AMGN) and Gilead (GILD), sporting a $22.9 billion market cap; however, that is down from its recent high of over $30 billion. Its stock has been trending downward since 2008.Its top drug, Revlimid, was initially approved in 2005 for a subset of myelodysplastic syndrome (MDS) patients after a highly successful Phase II trial. It went on to gain approval in multiple myeloma (MM), with sales hitting $1.7 billion in 2009. Complete Story » seekingalpha.com |
The Other Side of Genzyme Takeover Speculation Derek Lowe submits: In his classic Where Are the Customers' Yachts?, Fred Schwed mentions that the option market can be a good corrective when you're talking yourself into some investment idea. Take a look at it, he says, and you can see how many people are putting their own money down on the proposition that you might be wrong.Someone's doing just that with the Genzyme (GENZ) takeover speculation, according to the Wall Street Journal. Some trader opened up thousands of option contracts the other day, selling a pile of $75 October call options and opening up a January put spread between 55 and 65. I know that this is gibberish to most people who don't think about this stuff all the time, but what it means is that whoever this is doesn't think that Genzyme is going to make 75 by the end of October (or wants to be protected against the possibility that it won't), and will start to really clean up if the stock starts moving down below 55 again sometime before the end of January.Complete Story » seekingalpha.com |
Chelsea Soars on Positive Result for Blood Pressure Drug Second Time Around EP Vantage submits:It might have involved moving the goal posts, but Chelsea Therapeutics (CHTP) has finally gotten the results it wanted from a pivotal trial of lead product Northera, a therapy to treat dangerously low blood pressure (Event - Chelsea hopes new droxidopa trial stands tall, August 24, 2010). Shares in the company surged by 25% to $6.30 in early trade Monday, in response to the positive data, and are now trading at their highest level for nearly a year. With enough cash to last only into the first quarter of next year, Chelsea could well swiftly capitalize on this healthy gain to top up its coffers, via a share sale. Complete Story » seekingalpha.com |
Insurers Denied Coverage to 1 in 7 The four largest U.S. for-profit health insurers on average denied policies to one out of every seven applicants based on their prior medical history, according to a congressional investigation released Tuesday. online.wsj.com |